Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001217496 | SCV001389338 | uncertain significance | Immunodeficiency 31B; Autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome; Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency | 2022-02-18 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 946599). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with STAT1-related conditions. This variant is present in population databases (rs369060692, gnomAD 0.008%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 619 of the STAT1 protein (p.Arg619Gln). |
Ambry Genetics | RCV003284067 | SCV003955619 | uncertain significance | Inborn genetic diseases | 2023-05-05 | criteria provided, single submitter | clinical testing | The c.1856G>A (p.R619Q) alteration is located in exon 21 (coding exon 19) of the STAT1 gene. This alteration results from a G to A substitution at nucleotide position 1856, causing the arginine (R) at amino acid position 619 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |